Detail akcie Nascent Biotech online

Business Summary: Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.
Financial Summary: BRIEF: For the nine months ended 31 December 2023, Nascent Biotech Inc revenues was not reported. Net loss applicable to common stockholders decreased 31% to $1.6M. Lower net loss reflects Interest expense decrease of 64% to $363K (expense), Loss on original issuance discount decrease of 92% to $25K (expense), Clinical trials decrease of 62% to $82K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.02 to -$0.01.